دورية أكاديمية
Multicenter prospective observational study of dupilumab-induced ocular events in atopic dermatitis patients.
| العنوان: | Multicenter prospective observational study of dupilumab-induced ocular events in atopic dermatitis patients. |
|---|---|
| المؤلفون: | Costedoat, Ingrid, Wallaert, Martin, Gaultier, Aurélie, Vasseur, Robin, Vanhaecke, Clelia, Viguier, Manuelle, Cordelette, Charles, Denoyer, Alexandre, Ferrier Le Bouëdec, Marie-Christine, Coutu, Adrien, Lamiaux, Marie, Tran, Thi-Ha-Chau, Lacour, Jean-Philippe, Elmaleh, Valerie, Tetart, Florence, Gueudry, Julie, Tauber, Marie, Giordano-Labadie, Françoise, Cassagne, Myriam, Nosbaum, Audrey, Ouilhon, Coralie, Jachiet, Marie, Tadayoni, Ramin, Dezoteux, Frédéric, Staumont, delphine, Bouleau, Julien, Labalette, Pierre, Doan, Serge, Soria, Angele, Mortemousque, Bruno, Seneschal, Julien, Barbarot, Sebastien |
| المساهمون: | Université de Lille, Inserm, CHU Lille, CHU Bordeaux, Centre Hospitalier Universitaire de Nantes CHU Nantes, Hôpital universitaire Robert Debré Reims, CHU Clermont-Ferrand, Université catholique de Lille UCL, Centre Hospitalier Universitaire de Nice CHU Nice, CHU Rouen, Centre Hospitalier Universitaire de Toulouse CHU Toulouse, Hospices Civils de Lyon HCL, Centre International de Recherche en Infectiologie CIRI, Centre Hospitalier Lyon Sud CHU - HCL CHLS, Hopital Saint-Louis AP-HP AP-HP, Hôpital Lariboisière-Fernand-Widal APHP, Institute for Translational Research in Inflammation - U 1286 INFINITE (Ex-Liric), Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286, Centre Hospitalier Régional Universitaire CHU Lille CHRU Lille, CHU Tenon AP-HP |
| سنة النشر: | 2024 |
| المجموعة: | LillOA (Lille Open Archive - Université de Lille) |
| الوصف: | Background Although ocular adverse events are frequent in AD patients treated with dupilumab, their characterization remains limited due to a lack of prospective studies with a systematic ophthalmological examination. Objective To examine the incidence, characteristics and risk factors of dupilumab-induced ocular adverse events. Methods A prospective, multicenter, and real-life study in adult AD patients treated with dupilumab. Results At baseline, 27 out of 181 patients (14.9%) had conjunctivitis. At week 16 (W16), 25 out of 27 had improved their conjunctivitis and 2 remained stable and 34 out of 181 patients (18.7%) had dupilumab-induced blepharoconjunctivitis: either de novo (n = 32) or worsening of underlying blepharoconjunctivitis (n = 2). Most events (27/34; 79.4%) were moderate. A multivariate analysis showed that head and neck AD (OR = 7.254; 95%CI [1.938–30.07]; p = 0.004), erythroderma (OR = 5.635; 95%CI [1.635–21.50]; p = 0.007) and the presence of dry eye syndrome at baseline (OR = 3.51; 95%CI [3.158–13.90]; p = 0.031) were independent factors associated with dupilumab-induced blepharoconjunctivitis. Limitations Our follow-up period was 16 weeks and some late-onset time effects may still occur. Conclusion This study showed that most dupilumab-induced blepharoconjunctivitis cases are de novo. AD severity and conjunctivitis at baseline were not found to be associated risk factors in this study. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| تدمد: | 36732052 |
| العلاقة: | Journal of the European Academy of Dermatology and Venereology; J Eur Acad Dermatol Venereol; http://hdl.handle.net/20.500.12210/100638Test |
| الإتاحة: | https://doi.org/20.500.12210/100638Test https://hdl.handle.net/20.500.12210/100638Test |
| حقوق: | info:eu-repo/semantics/closedAccess |
| رقم الانضمام: | edsbas.852F8D24 |
| قاعدة البيانات: | BASE |
| تدمد: | 36732052 |
|---|